10-Q: Sagimet Advances MASH & Acne Programs, Reports Q3 Loss

Sagimet Biosciences reported a reduced net loss in Q3 2025, driven by lower R&D expenses, while advancing its denifanstat and TVB-3567 clinical programs for MASH and acne.

Summary

• Net loss for the three months ended September 30, 2025, was $12.9 million, a decrease from $14.6 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, increased to $41.5 million from $29.4 million for the same period in 2024.
• Research and development (R&D) expenses decreased by 23% to $9.7 million for Q3 2025, but increased by 33% to $32.3 million for the nine months ended September 30, 2025.
• General and administrative (G&A) expenses increased by 8% to $4.6 million for Q3 2025 and by 15% to $13.8 million for the nine months ended September 30, 2025.
• Cash, cash equivalents, and marketable securities totaled $125.5 million as of September 30, 2025, down from $158.2 million at December 31, 2024.
• Denifanstat met all primary and multiple secondary endpoints in the Phase 2b FASCINATE-2 clinical trial for MASH and received Breakthrough Therapy designation from the FDA.
• A Phase 1 pharmacokinetic (PK) clinical trial of a combination of denifanstat and resmetirom for MASH was initiated in September 2025.
• Ascletis BioScience Co. Ltd., Sagimet's license partner in China, announced denifanstat met all primary and secondary endpoints in its Phase 3 trial for moderate to severe acne vulgaris in June 2025.
• Ascletis completed pre-New Drug Application (NDA) consultation with the China National Medical Products Administration (NMPA) for denifanstat in acne in October 2025 and plans to submit an NDA soon.
• A first-in-human Phase 1 clinical trial of TVB-3567, a second FASN inhibitor for acne, was initiated in June 2025.
• The company entered into a Sales Agreement in August 2025 for an at-the-market (ATM) offering to sell up to $75.0 million of Series A common stock, with no sales under this ATM during Q3 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly positive. While the company shows strong clinical progress with denifanstat in MASH (Breakthrough Therapy, combination trial) and acne (Phase 3 success, NDA planning in China), and is expanding its pipeline with TVB-3567, the financial results indicate a significant increase in net loss for the nine-month period and a substantial decrease in cash reserves, highlighting ongoing capital requirements and burn rate. The ATM offering provides a funding mechanism but also signals future dilution risk.

Positives

• Denifanstat met all primary and multiple secondary endpoints in the Phase 2b FASCINATE-2 clinical trial for MASH, demonstrating anti-fibrotic activity.
• Denifanstat was granted Breakthrough Therapy designation by the U.S. FDA for MASH.
• The company initiated a Phase 1 PK clinical trial for a combination of denifanstat and resmetirom for MASH, building on preclinical data showing synergistic effects.
• Denifanstat met all primary and secondary endpoints in a Phase 3 trial for moderate to severe acne vulgaris in China, conducted by partner Ascletis.
• Ascletis completed pre-NDA consultation with the China NMPA for denifanstat in acne and plans to submit an NDA soon, indicating progress towards commercialization in China.
• Initiated a first-in-human Phase 1 clinical trial for TVB-3567, a new FASN inhibitor for acne, expanding the pipeline.

Negatives

• Net loss for the nine months ended September 30, 2025, increased significantly to $41.5 million from $29.4 million in the prior year period.
• Cash and cash equivalents decreased to $32.5 million as of September 30, 2025, from $75.8 million at December 31, 2024.
• Total cash, cash equivalents, and marketable securities decreased to $125.5 million as of September 30, 2025, from $158.1 million at December 31, 2024.
• Accumulated deficit increased to $336.8 million as of September 30, 2025, reflecting ongoing losses.
• Interest income decreased for both the three and nine-month periods due to a lower cash balance and lower yields.

Risks

• Ability to obtain additional cash and the sufficiency of existing cash, cash equivalents, and marketable securities to fund future operating expenses and capital expenditure requirements.
• Accuracy of estimates regarding expenses, future revenue, capital requirements, and needs for additional financing.
• Scope, progress, results, and costs of developing denifanstat, TVB-3567, or any other drug candidates or combination therapies, and conducting preclinical studies and clinical trials.
• Ability to advance drug candidates into, and successfully complete, clinical trials within anticipated timelines.
• Timing and costs involved in obtaining and maintaining regulatory approval of drug candidates, and the timing or likelihood of regulatory filings and approvals.
• Ability of clinical trials to demonstrate the safety and efficacy of drug candidates.
• Success of competing therapies that are or may become available.
• Ability to obtain sufficient funding or enter into a strategic collaboration to initiate Phase 3 clinical trials for denifanstat in MASH.
• Potential and ability to successfully manufacture and supply drug candidates for clinical trials and for commercial use, if approved.
• Impact of macroeconomic conditions and geopolitical turmoil on business and operations.

Future Outlook

The company expects research and development expenses to increase substantially as it advances drug candidates through preclinical studies and clinical trials, pursues regulatory approval, and expands its pipeline. General and administrative expenses are also expected to increase due to headcount growth and costs associated with operating as a public company. Topline data from the Phase 1 PK trial of denifanstat and resmetirom is anticipated in the first half of 2026. Subject to regulatory consultation and Phase 1 results, the company anticipates initiating a Phase 2 trial of TVB-3567 in 2026. The company believes its existing cash, cash equivalents, and marketable securities will fund operations for at least the next 12 months but will require substantial additional capital thereafter.

Management Comments

• Expect research and development expenses to increase substantially for the foreseeable future as drug candidates advance through clinical trials and regulatory approval.
• Expect general and administrative expenses to increase due to increased headcount and costs associated with operating as a public company.
• Believe existing cash, cash equivalents, and marketable securities as of September 30, 2025, will be sufficient to fund operating expenses for at least the next 12 months from the issuance of these financial statements.
• Will need to raise additional funds in the future until able to generate sufficient revenues to fund development activities.

Industry Context

Sagimet Biosciences operates in the clinical-stage biopharmaceutical sector, focusing on novel fatty acid synthase (FASN) inhibitors for metabolic and fibrotic diseases like MASH and acne. The development of denifanstat for MASH, including its Breakthrough Therapy designation and exploration of combination therapy with a THR-beta agonist like resmetirom (Rezdiffra), positions the company within a competitive and evolving landscape for liver disease treatments. The advancement of FASN inhibitors for acne also addresses a significant dermatological market, with partner Ascletis making progress towards NDA submission in China.

Comparison to Industry Standards

• Denifanstat's combination program with resmetirom (Rezdiffra), a thyroid hormone receptor beta (THR-β) agonist developed by Madrigal Pharmaceuticals, indicates a strategy to enhance efficacy in MASH, aligning with industry trends towards multi-modal approaches for complex diseases.
• Preclinical data showing synergistic effects of a FASN inhibitor (TVB-3664, surrogate for denifanstat) and resmetirom in mouse models of MASH, with 80% histological improvement (NAS ≥ 2 points) for the combination, significantly exceeds monotherapy results (33% for FASN inhibitor, 25% for resmetirom), suggesting a potentially superior therapeutic profile compared to single agents in the MASH pipeline.

Legal Proceedings

• The company is not party to any material legal proceedings as of September 30, 2025.

Related Party Transactions

• The license agreement with Ascletis BioScience Co. Ltd. (and its affiliate Gannex Pharma Co., Ltd.) for denifanstat in Greater China is considered a related party transaction, as Ascletis Pharma Inc. was a lead investor in the company's Series E financing.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises, such as the ATM offering, but also benefit from significant clinical progress and potential future commercialization of drug candidates.
• Employees are impacted by increased headcount and stock-based compensation plans, indicating growth and retention efforts.
• Patients stand to benefit from the continued development of novel FASN inhibitors for MASH and acne, with denifanstat showing promising results and advancing towards regulatory approval in certain indications and geographies.
• Creditors and suppliers are subject to the company's ongoing liquidity and ability to secure future financing to fund its operations and commitments.

Next Steps

• Anticipate topline data from the Phase 1 PK clinical trial of denifanstat and resmetirom combination in MASH in the first half of 2026.
• Plan to use Phase 1 PK data to inform optimal dose levels for a Phase 2 combination proof-of-concept efficacy trial in F4 MASH patients, subject to regulatory consultation.
• Ascletis plans to submit a New Drug Application (NDA) to the China National Medical Products Administration (NMPA) for denifanstat for moderate to severe acne vulgaris soon.
• Subject to consultation with regulatory authorities and contingent on Phase 1 trial results, anticipate initiating the Phase 2 trial of TVB-3567 in 2026.

Key Dates

Recommendation

Sagimet Biosciences presents a mixed investment profile. The significant clinical advancements for denifanstat in MASH, including Breakthrough Therapy designation and the initiation of a combination trial, along with the successful Phase 3 results for acne in China, are strong positive catalysts. The expansion of the pipeline with TVB-3567 further enhances long-term potential. However, the company's financial position shows an increasing net loss for the nine-month period and a substantial reduction in cash reserves, indicating a high burn rate typical of clinical-stage biotechs. The reliance on future capital raises, as evidenced by the ATM offering, introduces dilution risk. Given the promising pipeline balanced against the considerable financial needs and inherent risks of drug development, a 'hold' recommendation is appropriate for investors awaiting further clinical milestones and clearer paths to commercialization and sustainable funding.

Keywords

FASN inhibitor, MASH, NASH, acne, denifanstat, TVB-3567, biopharmaceutical, clinical-stage, fatty acid synthase, clinical trials, drug development, SEC filing